Covetrus Announces Real-Time Integration of Its Prescription Management Platform for eVetPractice® Users

Enhanced Integration Streamlines Veterinarian Experience, Making it
Easier to Drive Prescription Management to Improve Compliance

PORTLAND, Maine–(BUSINESS WIRE)–Covetrus (NASDAQ: CVET), a global leader in animal-health technology and
services, announced today that it has completed the real-time
integration of its cloud-based veterinary practice information
management system, eVetPractice®, with its prescription
management technology.

eVetPractice® joins Covetrus’ other leading practice
information management systems AVImark® and ImproMed®
in offering real-time, bi-directional integration with its cloud-based
prescription management technology. More than 16,000 practices
within the United States run on Covetrus’ practice information
management systems. This integration represents a major step forward as
Covetrus brings to market a cohesive set of technology services focused
on improving workflow and efficiency in the veterinary practice with
prescription management and compliance at the center.

We’re very pleased to offer practices that use AVImark, ImproMed, and,
now, eVetPractice an unparalleled level of integration with our
prescription management technology,” said Chris Dollar, senior vice
president of Covetrus Global Software Services. “Driving innovation,
enhancing our practice management capabilities and simplifying the
experience for our customers is at the core of our mission.”

Key benefits for the real-time integration include:

  • Synchronization between online prescription management and clinic
    software to ensure that veterinarians and their teams are able to view
    a complete history within their practice information management system
    without the need for double entry
  • The ability to coordinate and track the status of prescription
    authorizations and shipments within the clinical workflow in order to
    decrease time to therapy and enhance compliance
  • Streamlined processing to enhance productivity of the veterinary
    staff, and help re-direct resources to clinical and other
    administrative functions

Medical compliance for veterinary prescriptions, including preventative
medications, remains low at a time when the national incidence of flea,
tick and heartworm disease is on the rise. This underscores the need to
transform how veterinarians manage and engage their pet-owner clients to
help drive greater preventative awareness and improve medication
adherence.

Covetrus prescription management technology has demonstrated the ability
to drive two-to-four times improvement in compliance for prescriptions.
Streamlining this workflow through the tighter integration with the
practice management system can help eliminate administrative burden,
drive greater client engagement and improve health and financial
outcomes.

One of our top priorities was to integrate our eVetPractice and
prescription management capabilities to streamline and enhance
performance for the practices,” said Georgia Wraight, president of
Covetrus Global Prescription Management. “By automating documentation
and making prescription management easier for eVetPractice customers, we
can now deliver a more seamless experience and empower veterinarians
with tools to drive improved compliance.”

About Covetrus

Covetrus is a global animal-health technology and services company
dedicated to empowering veterinary practice partners to drive improved
health and financial outcomes. We’re bringing together products,
services, and technology into a single platform that connects our
customers to the solutions and insights they need to work best. Our
passion for the well-being of animals and those who care for them drives
us to advance the world of veterinary medicine. Covetrus is
headquartered in Portland, Maine, with more than 5,000 employees,
serving over 100,000 customers around the globe. For more information
about Covetrus visit https://www.covetrus.com.

Forward-Looking Statements

This press release contains certain statements that are forward-looking
within the meaning of Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange Act of 1934, as
amended, and that involve risks and uncertainties, including statements
about our future financial and operating results, plans, objectives,
expenses, expectations, intentions, trends in our business, our
liquidity, product development and improvements, and other matters. We
may, in some cases use terms such as “predicts,” “believes,”
“potential,” “continue,” “anticipates,” “estimates,” “expects,” “plans,”
“intends,” “may,” “could,” “might,” “likely,” “will,” “should” or other
words that convey uncertainty of the future events or outcomes to
identify these forward-looking statements. Such statements are subject
to numerous risks and uncertainties, including but not limited to, risks
associated with the ability to successfully integrate operations and
employees; the ability to realize anticipated benefits and synergies of
the transaction that created Covetrus; the potential impact of the
consummation of the transaction on relationships, including with
employees, customers and competitors; the ability to retain key
personnel; the ability to achieve performance targets; changes in
financial markets, interest rates and foreign currency exchange rates,
and those additional risks and factors discussed in our Annual Report on
Form 10-K filed on March 29, 2019 and Quarterly Report on Form 10-Q
filed for the quarter ended March 31, 2019, including those discussed
under the heading “Risk Factors.” Our forward-looking statements are
based on current beliefs and expectations of our management team and,
except as required by law, we undertake no obligations to make any
revisions to the forward-looking statements contained in this release or
to update them to reflect events or circumstances occurring after the
date of this release, whether as a result of new information, future
developments or otherwise. Investors are cautioned not to place undue
reliance on these forward-looking statements.

Contacts

Nicholas Jansen
Investor Relations
[email protected]
(207)
550-8106

Kiní Schoop
Public Relations
[email protected]
(207)
550-8018

error: Content is protected !!